Login to Your Account



STOCK SOARS 295 PERCENT

'I-SPY' revenge: Puma stalks Herceptin with stunning breast cancer data

By Marie Powers
Staff Writer

Wednesday, July 23, 2014
Three months ago, Puma Biotechnology Inc. ran into Wall Street headwinds on findings from its adaptive I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) trial of PB272 (neratinib), a pan-HER tyrosine kinase inhibitor, as neoadjuvant therapy in metastatic breast cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription